Exclusive: Roger Perlmutter on the biggest problem in Big Pharma, leaving Merck, and building Eikon

Andrew Dunn

Senior Biopharma Correspondent

HAYWARD, Calif. — After Roger Perlmutter stepped down as Merck’s head of R&D in 2021, he took a single weekend off before starting at Eikon Therapeutics …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Exclusive: Roger Perlmutter on the biggest problem in Big Pharma, leaving Merck, and building Eikon

Andrew Dunn

Senior Biopharma Correspondent

Sign up to read this article for free.

Sanofi, OpenAI, Formation Bio debut patient recruiting tool, will use in Phase 3 multiple sclerosis studies

Pfizer looking to sell hospital drugs unit — reports

Maze's ALS spinout Trace Neuroscience raises $101M for ALS and neuro work

'Expertise is a real thing': FDA commissioner warns of political risk to agency

Novartis pays $150M upfront to Schrödinger in new drug deal, ramps up software use

What Will It Take to Reverse Fibrosis in Patients with Advanced MASH?

Ex­clu­sive: Roger Perl­mut­ter on the biggest prob­lem in Big Phar­ma, leav­ing Mer­ck, and build­ing Eikon

Andrew Dunn

Senior Biopharma Correspondent

Sign up to read this article for free.

Sanofi, Ope­nAI, For­ma­tion Bio de­but pa­tient re­cruit­ing tool, will use in Phase 3 mul­ti­ple scle­ro­sis stud­ies

Pfiz­er look­ing to sell hos­pi­tal drugs unit — re­ports

Maze's ALS spin­out Trace Neu­ro­science rais­es $101M for ALS and neu­ro work

'Ex­per­tise is a re­al thing': FDA com­mis­sion­er warns of po­lit­i­cal risk to agency

No­var­tis pays $150M up­front to Schrödinger in new drug deal, ramps up soft­ware use

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

Exclusive: Roger Perlmutter on the biggest problem in Big Pharma, leaving Merck, and building Eikon

Sanofi, OpenAI, Formation Bio debut patient recruiting tool, will use in Phase 3 multiple sclerosis studies

Pfizer looking to sell hospital drugs unit — reports

Maze's ALS spinout Trace Neuroscience raises $101M for ALS and neuro work

'Expertise is a real thing': FDA commissioner warns of political risk to agency

Novartis pays $150M upfront to Schrödinger in new drug deal, ramps up software use

What Will It Take to Reverse Fibrosis in Patients with Advanced MASH?